| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/26/2004 | CA2496048A1 Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 02/26/2004 | CA2495452A1 Use of reboxetine for the treatment of hot flashes |
| 02/26/2004 | CA2495383A1 Fused benzene derivative and use |
| 02/26/2004 | CA2494847A1 Enos mutants useful for gene therapy |
| 02/26/2004 | CA2494539A1 Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer |
| 02/25/2004 | EP1391729A1 Antitumor antigen against htlv-1 tumor or antigen epitope thereof |
| 02/25/2004 | EP1391513A1 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| 02/25/2004 | EP1391512A1 Polypeptide serving as angiogenic marker and dna thereof |
| 02/25/2004 | EP1391464A1 Anti-cd40 monoclonal antibody |
| 02/25/2004 | EP1391461A1 Bicyclic lactam inhibitors of interleukin-1-beta converting enzyme |
| 02/25/2004 | EP1391457A1 Substituted 2-Phenylbenzimidazoles and their use as PARP inhibitors |
| 02/25/2004 | EP1391456A1 2-iminoimidazole derivative (2) |
| 02/25/2004 | EP1391451A1 2-iminopyrrolidine derivates |
| 02/25/2004 | EP1391221A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 02/25/2004 | EP1391213A1 Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| 02/25/2004 | EP1391206A1 Pharmaceutical compositions comprising arsenic for the treatment of lymphoma |
| 02/25/2004 | EP1391203A1 Antitumor agents |
| 02/25/2004 | EP1391197A1 Process for preparation of compositions with a high content in avarol and their use |
| 02/25/2004 | EP1390758A2 Method of identifying modulators of nogo-functions |
| 02/25/2004 | EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor |
| 02/25/2004 | EP1390543A2 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 02/25/2004 | EP1390516A1 Novel expression vectors and uses thereof |
| 02/25/2004 | EP1390512A1 A method for transfection of rna using electrical pulses |
| 02/25/2004 | EP1390508A2 A retinoic acid metabolizing cytochrome p450 |
| 02/25/2004 | EP1390507A2 Genes and proteins involved in the biosynthesis of enediyne ring structures |
| 02/25/2004 | EP1390502A2 Interferon-alpha induced gene |
| 02/25/2004 | EP1390497A2 Human cdnas and proteins and uses thereof |
| 02/25/2004 | EP1390410A1 Molecules for disease detection and treatment |
| 02/25/2004 | EP1390409A2 Monoclonal antibody neutralising cathepsin b activity and uses thereof |
| 02/25/2004 | EP1390406A2 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 02/25/2004 | EP1390405A2 Preparation of cholecystokinin agonists and antagonists and their therapeutic and diagnostic use |
| 02/25/2004 | EP1390403A2 Peptides derived from neural thread proteins and their medical use |
| 02/25/2004 | EP1390393A2 Pentapeptide compounds and uses related thereto |
| 02/25/2004 | EP1390391A1 Transporters and ion channels |
| 02/25/2004 | EP1390389A2 Cripto blocking antibodies and uses thereof |
| 02/25/2004 | EP1390385A2 Nucleic acid based modulation of female reproductive diseases and conditions |
| 02/25/2004 | EP1390384A2 Chromosome-based platforms |
| 02/25/2004 | EP1390383A1 Antisense permeation enhancers |
| 02/25/2004 | EP1390378A1 Pharmaceutically active uridine esters |
| 02/25/2004 | EP1390371A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors |
| 02/25/2004 | EP1390370A1 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| 02/25/2004 | EP1390369A1 4-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives |
| 02/25/2004 | EP1390368A1 Disubstituted 7,9-guaninium halides as telomerase inhibitors |
| 02/25/2004 | EP1390363A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 02/25/2004 | EP1390362A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 02/25/2004 | EP1390361A2 Melanocortin receptor ligands |
| 02/25/2004 | EP1390358A1 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent |
| 02/25/2004 | EP1390354A1 Triazinyl acrylamide derivatives as kinase inhibitors |
| 02/25/2004 | EP1390353A1 Triazole-derived kinase inhibitors and uses thereof |
| 02/25/2004 | EP1390349A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| 02/25/2004 | EP1390345A1 Polythiourea lipid derivatives |
| 02/25/2004 | EP1390343A1 Novel retinoid derivatives and methods for producing said compounds and an anti-cancer pharmaceutical composition comprising said compounds |
| 02/25/2004 | EP1390081A2 Therapeutic and diagnostic compounds, compositions, and methods |
| 02/25/2004 | EP1390080A1 Azo compounds for type i phototherapy |
| 02/25/2004 | EP1390075A2 Chemotherapeutic induction of egr-1 promoter activity |
| 02/25/2004 | EP1390071A2 Symbiotic regenerative agent |
| 02/25/2004 | EP1390065A2 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| 02/25/2004 | EP1390064A2 Method of treating malignancies through induction of blood immune responses |
| 02/25/2004 | EP1390057A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use |
| 02/25/2004 | EP1390054A2 Mu-conopeptides |
| 02/25/2004 | EP1390053A2 Hcg formulation |
| 02/25/2004 | EP1390046A2 Treatment of neoplasms with viruses |
| 02/25/2004 | EP1390033A1 Farnesyl protein transferase inhibitors for treating cachexia |
| 02/25/2004 | EP1390027A1 Composition comprising demethylcantharidin in combination with platinum-containing anticancer agents and use thereof |
| 02/25/2004 | EP1390025A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 02/25/2004 | EP1390018A1 A pharmaceutical tablet having a high api content |
| 02/25/2004 | EP1390013A2 Therapeutic treatments using the direct application of antimicrobial metal compositions |
| 02/25/2004 | EP1390011A2 Control of compactability through crystallization |
| 02/25/2004 | EP1389970A2 Compositions and methods of double-targeting virus infections and cancer cells |
| 02/25/2004 | EP1267902B1 Cosmetic use of hop and ornithine |
| 02/25/2004 | EP1263756B1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 02/25/2004 | EP1230232B1 Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/25/2004 | EP1210326B1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/25/2004 | EP1206447B1 Selective inhibitors of the urokinase plasminogene activators |
| 02/25/2004 | EP1200443B1 Aromatic esters of camptothecins and methods to treat cancers |
| 02/25/2004 | EP1181269B1 Cell proliferation inhibitors |
| 02/25/2004 | EP1149067B1 7-aryl-6(z)heptatrienoic acid retinamides as apoptosis inducing compounds and their use as anti-cancer agents |
| 02/25/2004 | EP1140931B1 5ht1 antagonists for antidepressant therapy |
| 02/25/2004 | EP1135481B1 New oligomeric conjugates liable to transfer biological molecules into cells |
| 02/25/2004 | EP1128812B1 Nano-emulsion of 5-aminolevulinic acid |
| 02/25/2004 | EP1080090B1 Antitumour 1,5-diazaanthraquinones |
| 02/25/2004 | EP1039908B1 Molecular dispersion composition with enhanced bioavailability |
| 02/25/2004 | EP0981620B1 Hgf polypeptides and their use in therapy |
| 02/25/2004 | EP0820515B1 Phospholipase c homolog |
| 02/25/2004 | CN1478146A Calcium binding proteins |
| 02/25/2004 | CN1478145A Differentiated cells suitable for human therapy |
| 02/25/2004 | CN1478143A Tumor cell internal specific proliferated virus capable of high-effectively expressing tumor angiogenesis inhibiting factor and its application |
| 02/25/2004 | CN1478098A Modulation of IL-2-and IL-15-mediated T cell responses |
| 02/25/2004 | CN1478091A Process for preparation of taxan derivatives |
| 02/25/2004 | CN1478090A Substituted imidazopyridines |
| 02/25/2004 | CN1478087A Indolylmaleimide derivatives as protein kinase C inibitors |
| 02/25/2004 | CN1478086A Process for crystallization of(R)-or(S)-lansoprazole |
| 02/25/2004 | CN1478084A Compounds useful in treatment of inflammatory diseases |
| 02/25/2004 | CN1478081A Substituted 2-znilino-benzimidazoles and use thereof as NHE-inhibitors |
| 02/25/2004 | CN1478078A Nitrogenous aromatic ring compounds |
| 02/25/2004 | CN1478072A Tetralone derivatives as antitumor agents |
| 02/25/2004 | CN1477977A Compositions of N-(methy/ethy/aminocarbony/)-4-(3-methy/pheny/amino)-3-pyridy/sulfonamide and cyclic oligosaccharides |
| 02/25/2004 | CN1477972A Method for botaining antigenic aggregates and use thereof in formulations |
| 02/25/2004 | CN1477968A Methods for treating rheumatic diseases using soluble CTLA4 molecule |
| 02/25/2004 | CN1477967A Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |